Clinical Trial

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2026 (before its estimated June 11, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
Trial Details
NCT Number NCT07421401
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Essential Hypertension
Enrollment 58 participants
Start Date 2026-04-13
Primary Completion 2026-06-11 (estimated)
Study Completion 2026-06-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-19